Patients with cervical cancer are needed for a study to research the disease will respond to an experimental drug vs. chemotherapy

UVA Tracking #
HSR200394
Principal Investigator
Linda R Duska
Contact
Anne Gabel
Contact Email
Contact Phone
434.982.6657
Official Trial Title
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, have cervical cancer, and have already tried 1-2 therapies to treat your cancer. The purpose of this study to evaluate 1 experimental drug (tisotumab vedotin) compared to chemotherapy in patients with cervical cancer. The safety and effects of the experimental drug will be evaluated for this study.
Participation includes a screening visit, drug treatment, and longer follow-up visits via a clinic visit or a phone call to keep track of how you are doing. You may receive drug as long as it continues to treat your disease. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04697628

Compensation

You will not receive compensation or reimbursement for this study.